Asher Biotherapeutics is a biotechnology startup that operates in the medical and healthcare market, specifically in the development of innovative immunotherapies. The company's primary focus is on cis-targeting, a novel approach to immunotherapy that offers a higher level of selectivity. This means that their therapies are designed to target and engage two receptors on the same immune cell, thereby only activating the immune response when the targeted antigen is present. This approach aims to optimize efficacy and minimize toxicity, potentially improving patient outcomes.

The company's lead product, AB248, is a cis-targeted IL-2 therapy. IL-2 is a powerful mediator of the immune system, and AB248 is designed to specifically activate CD8+ effector T cells, which play a crucial role in the body's immune response. Preliminary results suggest that AB248 may offer superior anti-tumor activity compared to other IL-2 targeted therapies currently available and in clinical development.

Asher Biotherapeutics' business model revolves around the research, development, and eventual commercialization of their cis-targeted immunotherapies. The company's primary clients are likely to be healthcare providers and patients in need of more effective and less toxic cancer treatments. The company generates revenue through the development and sale of its innovative therapies.

Keywords: Biotechnology, Immunotherapy, Cis-Targeting, Healthcare, Medical, Cancer Treatment, IL-2 Therapy, AB248, CD8+ Effector T Cells, Antigen.